Literature DB >> 17576527

[Costs involved in the early and late phases of diabetes mellitus].

A Liebl1.   

Abstract

The costs of diabetes mellitus type 2 in Germany are underestimated due to incomplete data. Especially in the first few years of the disease, the costs are significantly higher in diabetics than in persons without diabetes or other diabetes patients. The cost driver is inpatient treatment of diabetes complications. Glucose-lowering medications play a minor role. According to recent studies (CODE-2, CoDiM), the basic cost structure remains similar in later diabetes stages. For patients with complex complications, the costs are more than four times higher than in persons without diabetes. The enormous direct costs of diabetes account for 14.2% of total health care costs in Germany. Therapy for high blood pressure and blood glucose seem to be cost effective; data for modern lipid-lowering therapies are unclear. Thus, it is advisable to treat patients according to current guidelines and ethical considerations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576527     DOI: 10.1007/s00108-007-1875-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  18 in total

1.  [Costs of therapy of insulin-treated patients with Diabetes mellitus in Germany. Results of the JEVIN trial].

Authors:  Ralf Schiel; Ulrich A Müller; Günter Stein
Journal:  Med Klin (Munich)       Date:  2005-08-15

2.  Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).

Authors:  P M Clarke; A M Gray; A Briggs; R J Stevens; D R Matthews; R R Holman
Journal:  Diabetologia       Date:  2005-04-15       Impact factor: 10.122

3.  Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis.

Authors:  J B Brown; G A Nichols; H S Glauber; A W Bakst
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

Review 4.  [The costs of diabetes mellitus and its complications in Germany].

Authors:  H Hauner
Journal:  Dtsch Med Wochenschr       Date:  2006-12       Impact factor: 0.628

5.  Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.

Authors:  Borislava Mihaylova; Andrew Briggs; Jane Armitage; Sarah Parish; Alastair Gray; Rory Collins
Journal:  Lancet       Date:  2005 May 21-27       Impact factor: 79.321

6.  Medical costs of diabetic complications total costs and excess costs by age and type of treatment results of the German CoDiM Study.

Authors:  L von Ferber; I Köster; H Hauner
Journal:  Exp Clin Endocrinol Diabetes       Date:  2007-02       Impact factor: 2.949

Review 7.  [Disease modelling in diabetes mellitus].

Authors:  W Schramm; O Schöffski; A Görtz; A Liebl
Journal:  Dtsch Med Wochenschr       Date:  2004-10-22       Impact factor: 0.628

8.  Type II diabetes mellitus and impaired glucose regulation in Caucasian children and adolescents with obesity living in Germany.

Authors:  M Wabitsch; H Hauner; M Hertrampf; R Muche; B Hay; H Mayer; W Kratzer; K-M Debatin; E Heinze
Journal:  Int J Obes Relat Metab Disord       Date:  2004-02

9.  [Prevalence of diabetes mellitus in Germany 1998-2001. Secondary data analysis of a health insurance sample of the AOK in Hesse/KV in Hesse].

Authors:  H Hauner; I Köster; L von Ferber
Journal:  Dtsch Med Wochenschr       Date:  2003-12-12       Impact factor: 0.628

10.  [Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study].

Authors:  Andreas Liebl; Andrea Spannheimer; Ursula Reitberger; Anita Görtz
Journal:  Med Klin (Munich)       Date:  2002-12-15
View more
  4 in total

Review 1.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

Authors:  J G Garweg; A Wenzel
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

2.  International challenges without borders: a descriptive study of family physicians' educational needs in the field of diabetes.

Authors:  Suzanne Murray; Patrice Lazure; Sara Schroter; Philipp J Leuschner; Peter Posel; Thomas Kellner; Richard D Jenkins
Journal:  BMC Fam Pract       Date:  2011-05-11       Impact factor: 2.497

3.  Estimating the cost-effectiveness of lifestyle intervention programmes to prevent diabetes based on an example from Germany: Markov modelling.

Authors:  Anne Neumann; Peter Schwarz; Lars Lindholm
Journal:  Cost Eff Resour Alloc       Date:  2011-11-18

4.  Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective.

Authors:  Werner A Scherbaum; Gordon Goodall; Katrina M Erny-Albrecht; Massimo Massi-Benedetti; Erland Erdmann; William J Valentine
Journal:  Cost Eff Resour Alloc       Date:  2009-05-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.